Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vaccinia virus targets rectal tumors in new immunotherapy combo

NCT ID NCT07687875

Recruiting now Disease control Sponsor: Henry Smith Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase I trial tests a modified vaccinia virus (BT-001) injected directly into rectal tumors, followed by a single dose of the immunotherapy drug pembrolizumab. The study enrolls about 20 adults with localized pMMR rectal cancer who are candidates for surgery. The main goal is to evaluate safety and tolerability, with a secondary look at how well the combination shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BT-001 (modified vaccinia virus) and pembrolizumab (PD-1 blocking antibody)
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially reducing the need for more aggressive treatments like chemotherapy or radiation.
What could go wrong
This is a very early phase I trial with only 20 participants, focused on safety. The virus and drug combination may cause side effects, and it is unknown whether it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED RECTAL ADENOCARCINOMA WITH PROFICIENT MISMATCH REPAIR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER PATIENTS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Copenhagen University Hospital - Bispebjerg and Frederiksberg

    RECRUITING

    Copenhagen, Captial Region, 2400, Denmark

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.